Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery
2011

Evolution of Phosphoinositide Lipid Kinases and Their Role in Drug Discovery

publication Evidence: moderate

Author Information

Author(s): James R Brown, Kurt R Auger

Primary Institution: GlaxoSmithKline

Hypothesis

What are the evolutionary relationships of phosphoinositide lipid kinases (PIKs) across major eukaryotic groups and their implications for drug discovery?

Conclusion

The phylogenomic analysis of PIKs provides new insights into the evolution of second messenger signaling and suggests potential drug targets for various diseases.

Supporting Evidence

  • PIKs are critical for second messenger signaling and cellular membrane remodeling.
  • The study identifies four core eukaryotic PIKs and their evolutionary relationships.
  • Mutated PIK3CA are known to be oncogenic and several inhibitors are in anti-cancer clinical trials.
  • The analysis suggests that PIKs could be targeted for drug discovery in various diseases.

Takeaway

This study looks at how certain proteins help cells communicate and how understanding their evolution can help us find new medicines.

Methodology

The study involved phylogenetic analyses of phosphoinositide lipid kinases from various eukaryotic species using genomic data.

Limitations

The study may not cover all possible lipid kinase homologs and lacks data on some kinases.

Digital Object Identifier (DOI)

10.1186/1471-2148-11-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication